Biodexa Pharmaceuticals has registered the resale of up to 17,150 ordinary shares representing 343 American Depositary Shares, with selling shareholders identified as the sellers. The transaction matters to investors because it concerns a registered resale of existing securities rather than an issuer-led sale, while the ADSs remain listed on the Nasdaq Capital Market under BDRX.

Key Highlights

  • The resale securities have a nominal value of £0.000001 per ordinary share.
  • Selling shareholders, rather than Biodexa Pharmaceuticals, are identified as the sellers.
  • The 17,150 ordinary shares are represented by 343 American Depositary Shares.

The prospectus supplement covers the resale of securities by selling shareholders identified in the prospectus.

Resale Covers 17,150 Shares

The resale covers an aggregate of 17,150 ordinary shares. Each ordinary share carries a nominal value of £0.000001. The shares are represented by 343 American Depositary Shares. The prospectus identifies selling shareholders as the parties offering these securities for resale.

ADS Listing Remains BDRX

The listed ADSs represent the ordinary shares included in the resale registration. The prospectus supplement is dated September 11, 2026. It relates to the resale of the securities covered by the prospectus and includes information from Biodexa (NASDAQ: BDRX)’s interim results for the six months ended June 30, 2026. The securities covered are ordinary shares represented by ADSs. The resale covers 17,150 ordinary shares represented by 343 ADSs.